Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bilateral breast cancer

J Gogas1, C Markopoulos, P Skandalakis

  • 1Second Propedeutic Department of Surgery, University of Athens, Greece.

The American Surgeon
|November 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.

European journal of cancer (Oxford, England : 1990)·2023
Same author

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF<sup>V600</sup> mutation-positive melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Cobimetinib plus atezolizumab in BRAF<sup>V600</sup> wild-type melanoma: primary results from the randomized phase III IMspire170 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same journal

Complete Response of Merkel Cell Carcinoma to Immunotherapy and Single-Fraction Radiotherapy Following Severe COVID-19 Infection: A Case Report and Review of Immune Mechanism.

The American surgeon·2026
Same journal

Perioperative Acute Myocardial Infarction in Non-Cardiac Operations: A National Analysis.

The American surgeon·2026
Same journal

Outcomes of Completion Cholecystectomy: Association With Patient Comorbidity in a National Database.

The American surgeon·2026
Same journal

Building the Conversation: Editorial Stewardship in Contemporary Surgical Publishing.

The American surgeon·2026
Same journal

Musculoskeletal Pain in Surgeons on Operating Days.

The American surgeon·2026
Same journal

Splenectomy During Cytoreductive Surgery: Marker of Surgical Burden or Independent Predictor of Morbidity?

The American surgeon·2026
See all related articles

Developing a second primary breast cancer in the opposite breast is linked to younger age at diagnosis, family history, and lobular tumor type. These factors influence contralateral breast cancer risk.

Area of Science:

  • Oncology
  • Breast Cancer Research
  • Epidemiology

Background:

  • Contralateral breast cancer (CBC) is a significant concern for invasive breast cancer survivors.
  • Understanding risk factors for CBC is crucial for personalized patient management and surveillance strategies.

Purpose of the Study:

  • To investigate the incidence and risk factors associated with the development of second primary breast cancers in the contralateral breast.
  • To analyze the clinical and histopathological characteristics of bilateral breast cancers.

Main Methods:

  • Retrospective analysis of 1332 women diagnosed with invasive breast cancer over a 22-year period.
  • Classification of contralateral tumors into synchronous and metachronous groups.
  • Comparison of patient demographics, tumor characteristics, and family history between unilateral and bilateral breast cancer cases.

Related Experiment Videos

Main Results:

  • Seventy-eight cases of contralateral breast cancer were identified (incidence rate not explicitly stated but derived from percentages).
  • Metachronous contralateral breast cancers occurred at a mean interval of 117 months.
  • Patients with bilateral tumors were more likely to have a family history of breast cancer and tended to be younger at initial diagnosis.
  • Lobular invasive cancer was more frequent in first metachronous tumors.
  • Histopathologic type concordance was observed in 62.8% of bilateral cases, and estrogen receptor status concordance was 71.4%.

Conclusions:

  • Contralateral breast cancer risk is associated with patient's age at initial diagnosis, family history of breast cancer, and lobular histology.
  • The findings support the need for tailored surveillance and risk-reduction strategies based on these identified factors.